UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026
Rhea-AI Summary
UroGen Pharma (Nasdaq: URGN) will report first quarter 2026 financial results on Wednesday, May 6, 2026, prior to the market open. A live audio webcast and conference call will follow at 10:00 AM Eastern Time.
According to the company, the public webcast is accessible via its Investor Relations website and a replay will be available on the site for approximately 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – URGN
In the Apr 29 session, URGN declined 3.23%, reflecting a moderate negative market reaction. Argus tracked a peak move of +19.3% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 23 | Earnings date notice | Neutral | -0.7% | Announced timing and webcast details for Q4 and full-year 2025 results. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Past earnings date news showed a modest negative move, with an average same-tag reaction of -0.71% around such scheduling announcements.
Over recent months, UroGen has combined commercial and clinical progress with financial milestones. The company reported full-year 2025 results on Mar 2, 2026, including revenue of $109.8M and a net loss of $153.5M, alongside a pivotal ZUSDURI launch. Clinical visibility increased with Phase 3 ENVISION data published in the Journal of Urology. Today’s Q1 2026 earnings date notice follows a similar pattern to the prior fourth quarter earnings scheduling release announced on Feb 23, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call and Webcast Scheduled for Wednesday, May 6th, 2026, at 10:00 AM ET
PRINCETON, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report first quarter 2026 financial results on Wednesday, May 6th, 2026, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.
A live public webcast of the earnings conference call can be accessed on UroGen’s Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.UroGen.com to learn more or follow us on X, @UroGenPharma.
INVESTOR CONTACT:
Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093
MEDIA CONTACT:
Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3566 ext. 1083
FAQ
When will UroGen (URGN) report Q1 2026 earnings and when is the conference call?
UroGen will report Q1 2026 results on May 6, 2026 before the market opens and host a call.
According to the company, the live audio webcast and conference call are scheduled for 10:00 AM Eastern Time on that date.
How can investors access the UroGen (URGN) May 6, 2026 webcast and conference call?
Investors can join the live audio webcast via UroGen’s Investor Relations website at the scheduled time.
According to the company, the webcast is public and will be accessible on the Investor Relations site with details posted there ahead of the call.
Will a replay of the UroGen (URGN) May 6, 2026 earnings call be available and for how long?
A replay will be available after the live webcast and conference call for a limited time.
According to the company, the replay will remain accessible on the Investor Relations website for approximately 30 days following the live event.
Will UroGen (URGN) release financial tables or detailed results during the May 6, 2026 report?
The press notice confirms an earnings release and webcast but does not specify attachment formats or tables.
According to the company, the timing is prior to market open; investors should check the Investor Relations site for the full release and any accompanying tables.